Annual report
8129.TEDINET S100TX0G
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.48T | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥1.39T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.21T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.26T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥19.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥16.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥21.8bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥19.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.7bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥30.8bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥20.4bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥20.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.0bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥16.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥20.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥13.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥773.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥715.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥702.4bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥683.2bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥670.8bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥524.0bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥472.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥249.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥242.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥237.4bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥231.0bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥133.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥128.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥81.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥80.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥59.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥9m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥9.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥680m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥15.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥22.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥680m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥9.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥320.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.7 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.77 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥233.34 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥286.79 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.67 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.97 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥208.55 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥3,969.2 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,623.81 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,415.5 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,364.65 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,273.86 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.4% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 7,572 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 7,699 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 7,785 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 7,732 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 7,847 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥12.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥13.0bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.3bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥11.4bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥13.5bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥3.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥5.8bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥4.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.3bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥16.0bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥10.0bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥13.1bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥9.7bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥4.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥267.4bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥253.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥254.8bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥260.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥242.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥117.4bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥101.2bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥150.1bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥152.3bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥154.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥160.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥150.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥121.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥74.8bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥203.27 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥139.32 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.91 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥145.29 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥139.74 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥182.03 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥127.91 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥52.22 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥133.57 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥124.8 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥40 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,387.4 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,271.65 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,191.82 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,275.25 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,129.58 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 56.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.0% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.7% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.5% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 76,431,342 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 192 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 192 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 224 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 227 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 233 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥923m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥58.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥58.3bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥93.6bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥2.9bn |
| Dispensing Pharmacyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥647m |
| Dispensing Pharmacyreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥903m |
| Dispensing Pharmacyreportable segment | employees | at 2024-03-31 | 2546 pure |
| Dispensing Pharmacyreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥93.8bn |
| Dispensing Pharmacyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥93.8bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥15m |
| Dispensing Pharmacyreportable segment | segment assets | at 2024-03-31 | ¥56.8bn |
| Dispensing Pharmacyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Medical Products Manufacturing And Salesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥157m |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥162m |
| Medical Products Manufacturing And Salesreportable segment | employees | at 2024-03-31 | 101 pure |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.6bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥8.2bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2024-03-31 | ¥19.3bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥755m |
| Medical Products Retailreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.2bn |
| Medical Products Retailreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| Medical Products Retailreportable segment | employees | at 2024-03-31 | 4530 pure |
| Medical Products Retailreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.42T |
| Medical Products Retailreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.38T |
| Medical Products Retailreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥48.7bn |
| Medical Products Retailreportable segment | segment assets | at 2024-03-31 | ¥598.3bn |
| Medical Products Retailreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥1.54T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥1.48T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥58.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥679.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥22.2bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥111m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥57.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥57.1bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥72.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.5bn |
| Dispensing Pharmacyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥584m |
| Dispensing Pharmacyreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥922m |
| Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥92.3bn |
| Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥92.3bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥8m |
| Dispensing Pharmacyreportable segment | segment assets | at 2023-03-31 | ¥55.8bn |
| Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.4bn |
| Medical Products Manufacturing And Salesreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥135m |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥187m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9.9bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.8bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2023-03-31 | ¥18.1bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥864m |
| Medical Products Retailreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Medical Products Retailreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥3.2bn |
| Medical Products Retailreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.34T |
| Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.29T |
| Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥47.6bn |
| Medical Products Retailreportable segment | segment assets | at 2023-03-31 | ¥562.8bn |
| Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥14.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥1.45T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥1.39T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥57.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥642.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥17.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,070
| Item | Context | Value | Unit |
|---|---|---|---|
| Other noi | CurrentYearDuration_NonConsolidatedMember | 230000000 | JPY |
| Non operating income | Prior1YearDuration_NonConsolidatedMember | 1809000000 | JPY |
| Non operating income | CurrentYearDuration_NonConsolidatedMember | 1842000000 | JPY |
| Interest expenses noe | Prior1YearDuration_NonConsolidatedMember | 341000000 | JPY |
| Interest expenses noe | CurrentYearDuration_NonConsolidatedMember | 372000000 | JPY |
| Bond issuance cost noe | Prior1YearDuration_NonConsolidatedMember | － | JPY |
| Bond issuance cost noe | CurrentYearDuration_NonConsolidatedMember | 83000000 | JPY |
| Commitment fee noe | Prior1YearDuration_NonConsolidatedMember | 1000000 | JPY |
| Commitment fee noe | CurrentYearDuration_NonConsolidatedMember | 1000000 | JPY |
| Provision for loss on guarantees noe | Prior1YearDuration_NonConsolidatedMember | － | JPY |
| Provision for loss on guarantees noe | CurrentYearDuration_NonConsolidatedMember | 148000000 | JPY |
| Other noe | Prior1YearDuration_NonConsolidatedMember | 30000000 | JPY |
| Other noe | CurrentYearDuration_NonConsolidatedMember | 162000000 | JPY |
| Non operating expenses | Prior1YearDuration_NonConsolidatedMember | 373000000 | JPY |
| Non operating expenses | CurrentYearDuration_NonConsolidatedMember | 766000000 | JPY |
| Ordinary income | Prior1YearDuration_NonConsolidatedMember | 7260000000 | JPY |
| Ordinary income | CurrentYearDuration_NonConsolidatedMember | 4883000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YearDuration_NonConsolidatedMember | 4000000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYearDuration_NonConsolidatedMember | 18000000 | JPY |
| Gain on sales of investment securities ei | Prior1YearDuration_NonConsolidatedMember | 4193000000 | JPY |
| Gain on sales of investment securities ei | CurrentYearDuration_NonConsolidatedMember | 11337000000 | JPY |
| Other ei | Prior1YearDuration_NonConsolidatedMember | 2000000 | JPY |
| Other ei | CurrentYearDuration_NonConsolidatedMember | 0 | JPY |
| Extraordinary income | Prior1YearDuration_NonConsolidatedMember | 4200000000 | JPY |
| Extraordinary income | CurrentYearDuration_NonConsolidatedMember | 11356000000 | JPY |
| Loss on disposal of noncurrent assets el | Prior1YearDuration_NonConsolidatedMember | 23000000 | JPY |
| Loss on disposal of noncurrent assets el | CurrentYearDuration_NonConsolidatedMember | 103000000 | JPY |
| Impairment loss el | Prior1YearDuration_NonConsolidatedMember | 7000000 | JPY |
| Impairment loss el | CurrentYearDuration_NonConsolidatedMember | 12000000 | JPY |
| Loss on valuation of investment securities el | Prior1YearDuration_NonConsolidatedMember | 323000000 | JPY |
| Loss on valuation of investment securities el | CurrentYearDuration_NonConsolidatedMember | 135000000 | JPY |
| Loss on midterm cancellation of contracts el | Prior1YearDuration_NonConsolidatedMember | 608000000 | JPY |
| Loss on midterm cancellation of contracts el | CurrentYearDuration_NonConsolidatedMember | － | JPY |
| Other el | Prior1YearDuration_NonConsolidatedMember | 480000000 | JPY |
| Other el | CurrentYearDuration_NonConsolidatedMember | 11000000 | JPY |
| Extraordinary loss | Prior1YearDuration_NonConsolidatedMember | 1442000000 | JPY |
| Extraordinary loss | CurrentYearDuration_NonConsolidatedMember | 262000000 | JPY |
| Income before income taxes | Prior1YearDuration_NonConsolidatedMember | 10018000000 | JPY |
| Income before income taxes | CurrentYearDuration_NonConsolidatedMember | 15977000000 | JPY |
| Income taxes current | Prior1YearDuration_NonConsolidatedMember | 910000000 | JPY |
| Income taxes current | CurrentYearDuration_NonConsolidatedMember | 3158000000 | JPY |
| Income taxes deferred | Prior1YearDuration_NonConsolidatedMember | -547000000 | JPY |
| Income taxes deferred | CurrentYearDuration_NonConsolidatedMember | -299000000 | JPY |
| Income taxes | Prior1YearDuration_NonConsolidatedMember | 362000000 | JPY |
| Income taxes | CurrentYearDuration_NonConsolidatedMember | 2858000000 | JPY |
| Profit loss | Prior1YearDuration_NonConsolidatedMember | 9655000000 | JPY |
| Profit loss | CurrentYearDuration_NonConsolidatedMember | 13118000000 | JPY |
| Net assets | Prior2YearInstant_NonConsolidatedMember_CapitalStockMember | 10649000000 | JPY |
| Net assets | Prior2YearInstant_NonConsolidatedMember_LegalCapitalSurplusMember | 46177000000 | JPY |
| Net assets | Prior2YearInstant_NonConsolidatedMember_OtherCapitalSurplusMember | 3933000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |